Zheng Quan Ri Bao Wang·2026-01-13 07:17Core Insights - A milestone solution for infant vascular tumor treatment has been launched in China, with the modified new drug, Malate Timolol Gel (brand name: Beimeijing), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after twelve years of research [1] - The drug is the first and only approved topical gel formulation for treating "proliferative superficial infantile hemangiomas," marking a significant advancement for China in this medical field [1] - Beimeijing has received national-level price certification, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Overview - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The "golden window period" for effective intervention is within the first 1-6 months after birth, as failure to treat during this period can lead to permanent skin issues [2] - Traditional treatment methods have limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - Beimeijing's development was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, with a comprehensive approach from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and pain-free option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data showed that among 121 infants aged 1-6 months, 60.7% achieved clinical cure (Grade IV improvement) after 24 weeks of treatment, with an overall efficacy rate of 89.4% and good safety profile [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the child, ensuring that the standardized treatment approach represented by Beimeijing reaches every family in need [3]